Filing Flows › Aligos Therapeutics (ALGS) › Q3 2025
Aligos Therapeutics (ALGS) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 6, 2025
Aligos Therapeutics (ALGS) reported revenue of $741K for the third quarter 2025 (Q3 2025), -41% from a year earlier and -23% from the quarter before.
Aligos Therapeutics, Q3 2025: revenue $741K (-41% year over year), net loss $31.5M, operating cash flow −$24.3M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $741K | -23% | -41% |
| Operating profit | −$28.4M | — | — |
| Net earnings | −$31.5M | — | — |
| Operating cash flow | −$24.3M | — | — |
What changed
Revenue was $741K in Q3 2025, down 41% year over year and down 23% from the previous quarter.
Operating costs exceeded revenue by $28.4M, an operating margin of -3827.4%. Total costs grew 36% against a revenue fall of 41%. The fastest-growing cost line was Research & development (+43%). The quarter ended with a net loss of $31.5M, wider than the previous quarter's $15.9M loss.
Operating cash flow was −$24.3M. Non-cash charges added back $200K of depreciation and $1.5M of share-based compensation. Working capital and other items added $5.5M.
Questions
What was Aligos Therapeutics' revenue in the third quarter 2025?
Aligos Therapeutics (ALGS) reported revenue of $741K for the third quarter 2025 (Q3 2025), -41% from a year earlier and -23% from the quarter before.